Phase I Trial Of Escalating Oral Doses Of SCH 66336 In Pediatric Patients With Refractory Or Recurrent Brain Tumors

Trial Profile

Phase I Trial Of Escalating Oral Doses Of SCH 66336 In Pediatric Patients With Refractory Or Recurrent Brain Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Oct 2009

At a glance

  • Drugs Lonafarnib (Primary)
  • Indications Brain cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 20 Oct 2009 Actual patient number (53) added as reported by ClinicalTrials.gov.
    • 21 Aug 2007 Status change from in progress to completed.
    • 15 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top